ID   PGBM_HUMAN              Reviewed;        4391 AA.
AC   P98160; Q16287; Q5SZI3; Q9H3V5;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 4.
DT   10-MAY-2017, entry version 198.
DE   RecName: Full=Basement membrane-specific heparan sulfate proteoglycan core protein;
DE            Short=HSPG;
DE   AltName: Full=Perlecan;
DE            Short=PLC;
DE   Contains:
DE     RecName: Full=Endorepellin;
DE   Contains:
DE     RecName: Full=LG3 peptide;
DE   Flags: Precursor;
GN   Name=HSPG2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS VAL-638; SER-765 AND
RP   VAL-1503.
RC   TISSUE=Colon, and Skin;
RX   PubMed=1569102;
RA   Murdoch A.D., Dodge G.R., Cohen I., Tuan R.S., Iozzo R.V.;
RT   "Primary structure of the human heparan sulfate proteoglycan from
RT   basement membrane (HSPG2/perlecan). A chimeric molecule with multiple
RT   domains homologous to the low density lipoprotein receptor, laminin,
RT   neural cell adhesion molecules, and epidermal growth factor.";
RL   J. Biol. Chem. 267:8544-8557(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS VAL-638; SER-765; VAL-1503;
RP   HIS-2980; GLY-2995; THR-3168 AND GLN-3632.
RX   PubMed=1730768; DOI=10.1083/jcb.116.2.559;
RA   Kallunki P., Tryggvason K.;
RT   "Human basement membrane heparan sulfate proteoglycan core protein: a
RT   467-kD protein containing multiple domains resembling elements of the
RT   low density lipoprotein receptor, laminin, neural cell adhesion
RT   molecules, and epidermal growth factor.";
RL   J. Cell Biol. 116:559-571(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-21.
RX   PubMed=8234307; DOI=10.1073/pnas.90.21.10404;
RA   Cohen I.R., Graessel S., Murdoch A.D., Iozzo R.V.;
RT   "Structural characterization of the complete human perlecan gene and
RT   its promoter.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10404-10408(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 22-4391, VARIANTS VAL-638 AND
RP   SJS1 TYR-1532, AND VARIANTS SER-765 AND VAL-1503.
RX   PubMed=11101850; DOI=10.1038/82638;
RA   Nicole S., Davoine C.-S., Topaloglu H., Cattolico L., Barral D.,
RA   Beighton P., Ben-Hamida C., Hammouda H., Cruaud C., White P.S.,
RA   Samson D., Urtizberea J.A., Lehmann-Horn F., Weissenbach J.,
RA   Hentati F., Fontaine B.;
RT   "Perlecan, the major proteoglycan of basement membranes, is altered in
RT   patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia).";
RL   Nat. Genet. 26:480-483(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 890-1396.
RC   TISSUE=Fibrosarcoma;
RX   PubMed=1685141;
RA   Kallunki P., Eddy R.L., Byers M.G., Kestila M., Shows T.B.,
RA   Tryggvason K.;
RT   "Cloning of human heparan sulfate proteoglycan core protein,
RT   assignment of the gene (HSPG2) to 1p36.1-->p35 and identification of a
RT   BamHI restriction fragment length polymorphism.";
RL   Genomics 11:389-396(1991).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1016-1470.
RC   TISSUE=Colon;
RX   PubMed=1679749; DOI=10.1016/0888-7543(91)90451-J;
RA   Dodge G.R., Kovalszky I., Chu M.-L., Hassell J.R., McBride O.W.,
RA   Yi H.F., Iozzo R.V.;
RT   "Heparan sulfate proteoglycan of human colon: partial molecular
RT   cloning, cellular expression, and mapping of the gene (HSPG2) to the
RT   short arm of human chromosome 1.";
RL   Genomics 10:673-680(1991).
RN   [8]
RP   PROTEIN SEQUENCE OF 1379-1398 AND 2259-2278.
RX   PubMed=2687294; DOI=10.1083/jcb.109.6.3199;
RA   Heremans A., van der Schueren B., de Cock B., Paulsson M.,
RA   Cassiman J.-J., van den Berghe H., David G.;
RT   "Matrix-associated heparan sulfate proteoglycan: core protein-specific
RT   monoclonal antibodies decorate the pericellular matrix of connective
RT   tissue cells and the stromal side of basement membranes.";
RL   J. Cell Biol. 109:3199-3211(1989).
RN   [9]
RP   PROTEIN SEQUENCE OF 4197-4208, PROTEOLYTIC PROCESSING AT ASN-4196,
RP   FUNCTION OF LG3 PEPTIDE, GLYCOSYLATION, AND MUTAGENESIS OF ASP-4197;
RP   ASP-4258 AND ASN-4327.
RX   PubMed=15591058; DOI=10.1074/jbc.M409841200;
RA   Gonzalez E.M., Reed C.C., Bix G., Fu J., Zhang Y., Gopalakrishnan B.,
RA   Greenspan D.S., Iozzo R.V.;
RT   "BMP-1/Tolloid-like metalloproteases process endorepellin, the
RT   angiostatic C-terminal fragment of perlecan.";
RL   J. Biol. Chem. 280:7080-7087(2005).
RN   [10]
RP   PROTEIN SEQUENCE OF 4197-4203, PROTEOLYTIC PROCESSING AT ASN-4196, AND
RP   FUNCTION OF ENDOREPELLIN AND LG3 PEPTIDE.
RX   PubMed=12435733; DOI=10.1074/jbc.M210445200;
RA   Mongiat M., Sweeney S.M., San Antonio J.D., Fu J., Iozzo R.V.;
RT   "Endorepellin, a novel inhibitor of angiogenesis derived from the C
RT   terminus of perlecan.";
RL   J. Biol. Chem. 278:4238-4249(2003).
RN   [11]
RP   INTERACTION WITH FGFBP1.
RX   PubMed=11148217; DOI=10.1074/jbc.M011493200;
RA   Mongiat M., Otto J., Oldershaw R., Ferrer F., Sato J.D., Iozzo R.V.;
RT   "Fibroblast growth factor-binding protein is a novel partner for
RT   perlecan protein core.";
RL   J. Biol. Chem. 276:10263-10271(2001).
RN   [12]
RP   INVOLVEMENT IN DDSH.
RX   PubMed=11279527; DOI=10.1038/86941;
RA   Arikawa-Hirasawa E., Wilcox W.R., Le A.H., Silverman N., Govindraj P.,
RA   Hassell J.R., Yamada Y.;
RT   "Dyssegmental dysplasia, Silverman-Handmaker type, is caused by
RT   functional null mutations of the perlecan gene.";
RL   Nat. Genet. 27:431-434(2001).
RN   [13]
RP   INTERACTION WITH COL13A1.
RX   PubMed=11956183; DOI=10.1074/jbc.M107583200;
RA   Tu H., Sasaki T., Snellman A., Gohring W., Pirila P., Timpl R.,
RA   Pihlajaniemi T.;
RT   "The type XIII collagen ectodomain is a 150-nm rod and capable of
RT   binding to fibronectin, nidogen-2, perlecan, and heparin.";
RL   J. Biol. Chem. 277:23092-23099(2002).
RN   [14]
RP   INTERACTION WITH ECM1.
RX   PubMed=12604605; DOI=10.1074/jbc.M210529200;
RA   Mongiat M., Fu J., Oldershaw R., Greenhalgh R., Gown A.M., Iozzo R.V.;
RT   "Perlecan protein core interacts with extracellular matrix protein 1
RT   (ECM1), a glycoprotein involved in bone formation and angiogenesis.";
RL   J. Biol. Chem. 278:17491-17499(2003).
RN   [15]
RP   GLYCOSYLATION AT ASN-2121.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [16]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-1755.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [17]
RP   FUNCTION OF ENDOREPELLIN.
RX   PubMed=17105986; DOI=10.1093/jnci/djj441;
RA   Bix G., Castello R., Burrows M., Zoeller J.J., Weech M., Iozzo R.A.,
RA   Cardi C., Thakur M.L., Barker C.A., Camphausen K., Iozzo R.V.;
RT   "Endorepellin in vivo: targeting the tumor vasculature and retarding
RT   cancer growth and metabolism.";
RL   J. Natl. Cancer Inst. 98:1634-1646(2006).
RN   [18]
RP   FUNCTION OF ENDOREPELLIN, AND IDENTIFICATION OF RECEPTOR.
RX   PubMed=18024432; DOI=10.1074/jbc.M708364200;
RA   Woodall B.P., Nystroem A., Iozzo R.A., Eble J.A., Niland S., Krieg T.,
RA   Eckes B., Pozzi A., Iozzo R.V.;
RT   "Integrin alpha2beta1 is the required receptor for endorepellin
RT   angiostatic activity.";
RL   J. Biol. Chem. 283:2335-2343(2008).
RN   [19]
RP   FUNCTION.
RX   PubMed=19789387; DOI=10.1182/blood-2009-02-207134;
RA   Nystrom A., Shaik Z.P., Gullberg D., Krieg T., Eckes B., Zent R.,
RA   Pozzi A., Iozzo R.V.;
RT   "Role of tyrosine phosphatase SHP-1 in the mechanism of endorepellin
RT   angiostatic activity.";
RL   Blood 114:4897-4906(2009).
RN   [20]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-554; ASN-1755; ASN-3072;
RP   ASN-3780; ASN-3836 AND ASN-4068.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [21]
RP   GLYCOSYLATION AT THR-42, STRUCTURE OF CARBOHYDRATES, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22171320; DOI=10.1074/mcp.M111.013649;
RA   Halim A., Nilsson J., Ruetschi U., Hesse C., Larson G.;
RT   "Human urinary glycoproteomics; attachment site specific analysis of
RT   N-and O-linked glycosylations by CID and ECD.";
RL   Mol. Cell. Proteomics 0:0-0(2011).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 4197-4391, DISULFIDE BOND,
RP   AND CALCIUM-BINDING SITES.
RX   PubMed=21996443; DOI=10.1016/j.jmb.2011.09.048;
RA   Le B.V., Kim H., Choi J., Kim J.H., Hahn M.J., Lee C., Kim K.K.,
RA   Hwang H.Y.;
RT   "Crystal structure of the LG3 domain of endorepellin, an angiogenesis
RT   inhibitor.";
RL   J. Mol. Biol. 414:231-242(2011).
CC   -!- FUNCTION: Integral component of basement membranes. Component of
CC       the glomerular basement membrane (GBM), responsible for the fixed
CC       negative electrostatic membrane charge, and which provides a
CC       barrier which is both size- and charge-selective. It serves as an
CC       attachment substrate for cells. Plays essential roles in
CC       vascularization. Critical for normal heart development and for
CC       regulating the vascular response to injury. Also required for
CC       avascular cartilage development.
CC   -!- FUNCTION: Endorepellin in an anti-angiogenic and anti-tumor
CC       peptide that inhibits endothelial cell migration, collagen-induced
CC       endothelial tube morphogenesis and blood vessel growth in the
CC       chorioallantoic membrane. Blocks endothelial cell adhesion to
CC       fibronectin and type I collagen. Anti-tumor agent in
CC       neovascularization. Interaction with its ligand, integrin
CC       alpha2/beta1, is required for the anti-angiogenic properties.
CC       Evokes a reduction in phosphorylation of receptor tyrosine kinases
CC       via alpha2/beta1 integrin-mediated activation of the tyrosine
CC       phosphatase, PTPN6.
CC   -!- FUNCTION: The LG3 peptide has anti-angiogenic properties that
CC       require binding of calcium ions for full activity.
CC   -!- SUBUNIT: Purified perlecan has a strong tendency to aggregate in
CC       dimers or stellate structures. It interacts with other basement
CC       membrane components such as laminin, prolargin and collagen type
CC       IV. Interacts with COL13A1, FGFBP1 and VWA1. Interacts (via C-
CC       terminus) with ECM1 (via C-terminus).
CC       {ECO:0000269|PubMed:11148217, ECO:0000269|PubMed:11956183,
CC       ECO:0000269|PubMed:12604605}.
CC   -!- INTERACTION:
CC       P17948-2:FLT1; NbExp=2; IntAct=EBI-6896259, EBI-6530464;
CC       P35968:KDR; NbExp=5; IntAct=EBI-947664, EBI-1005487;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix, basement membrane.
CC   -!- TISSUE SPECIFICITY: Found in the basement membranes.
CC   -!- PTM: Proteolytic processing produces the C-terminal angiogenic
CC       peptide, endorepellin. This peptide can be further processed to
CC       produce the LG3 peptide. {ECO:0000269|PubMed:12435733,
CC       ECO:0000269|PubMed:15591058}.
CC   -!- PTM: N- and O-glycosylated. O-glycosylated with core 1 or possibly
CC       core 8 glycans. Perlecan contains three heparan sulfate chains.
CC       The LG3 peptide contains at least three and up to five potential
CC       O-glycosylation sites but no N-glycosylation.
CC       {ECO:0000269|PubMed:12754519, ECO:0000269|PubMed:15591058,
CC       ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:22171320}.
CC   -!- DISEASE: Schwartz-Jampel syndrome (SJS1) [MIM:255800]: Rare
CC       autosomal recessive disorder characterized by permanent myotonia
CC       (prolonged failure of muscle relaxation) and skeletal dysplasia,
CC       resulting in reduced stature, kyphoscoliosis, bowing of the
CC       diaphyses and irregular epiphyses. {ECO:0000269|PubMed:11101850}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Dyssegmental dysplasia Silverman-Handmaker type (DDSH)
CC       [MIM:224410]: The dyssegmental dysplasias are rare, autosomal
CC       recessive skeletal dysplasias with anisospondyly and micromelia.
CC       There are two recognized types: the severe, lethal DDSH and the
CC       milder Rolland-Desbuquois form. Individuals with DDSH also have a
CC       flat face, micrognathia, cleft palate and reduced joint mobility,
CC       and frequently have an encephalocoele. The endochondral growth
CC       plate is short, the calcospherites (which are spherical calcium-
CC       phosphorus crystals produced by hypertrophic chondrocytes) are
CC       unfused, and there is mucoid degeneration of the resting
CC       cartilage. {ECO:0000269|PubMed:11279527}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: The LG3 peptide has been found in the urine of
CC       patients with end-stage renal disease and in the amniotic fluid of
CC       pregnant women with premature rupture of fetal membranes.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/HSPG2ID40890ch1p36.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Perlecan entry;
CC       URL="https://en.wikipedia.org/wiki/Perlecan";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M85289; AAA52700.1; -; mRNA.
DR   EMBL; X62515; CAA44373.1; -; mRNA.
DR   EMBL; AL590556; CAH71870.1; -; Genomic_DNA.
DR   EMBL; AL590103; CAH71870.1; JOINED; Genomic_DNA.
DR   EMBL; AL590103; CAI12125.1; -; Genomic_DNA.
DR   EMBL; AL590556; CAI12125.1; JOINED; Genomic_DNA.
DR   EMBL; L22078; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL445795; CAC18534.1; -; Genomic_DNA.
DR   EMBL; S76436; AAB21121.2; -; mRNA.
DR   EMBL; M64283; AAA52699.1; -; mRNA.
DR   CCDS; CCDS30625.1; -.
DR   PIR; A38096; A38096.
DR   RefSeq; NP_001278789.1; NM_001291860.1.
DR   RefSeq; NP_005520.4; NM_005529.6.
DR   UniGene; Hs.562227; -.
DR   PDB; 3SH4; X-ray; 1.50 A; A=4197-4391.
DR   PDB; 3SH5; X-ray; 2.80 A; A=4197-4391.
DR   PDBsum; 3SH4; -.
DR   PDBsum; 3SH5; -.
DR   ProteinModelPortal; P98160; -.
DR   SMR; P98160; -.
DR   BioGrid; 109571; 32.
DR   IntAct; P98160; 30.
DR   MINT; MINT-123304; -.
DR   STRING; 9606.ENSP00000363827; -.
DR   DrugBank; DB00039; Palifermin.
DR   iPTMnet; P98160; -.
DR   PhosphoSitePlus; P98160; -.
DR   UniCarbKB; P98160; -.
DR   BioMuta; HSPG2; -.
DR   DMDM; 317373536; -.
DR   DOSAC-COBS-2DPAGE; P98160; -.
DR   EPD; P98160; -.
DR   MaxQB; P98160; -.
DR   PaxDb; P98160; -.
DR   PeptideAtlas; P98160; -.
DR   PRIDE; P98160; -.
DR   Ensembl; ENST00000374695; ENSP00000363827; ENSG00000142798.
DR   GeneID; 3339; -.
DR   KEGG; hsa:3339; -.
DR   UCSC; uc001bfj.4; human.
DR   CTD; 3339; -.
DR   DisGeNET; 3339; -.
DR   GeneCards; HSPG2; -.
DR   H-InvDB; HIX0023554; -.
DR   H-InvDB; HIX0023598; -.
DR   HGNC; HGNC:5273; HSPG2.
DR   HPA; CAB009820; -.
DR   HPA; CAB020718; -.
DR   HPA; HPA018892; -.
DR   MalaCards; HSPG2; -.
DR   MIM; 142461; gene.
DR   MIM; 224410; phenotype.
DR   MIM; 255800; phenotype.
DR   neXtProt; NX_P98160; -.
DR   OpenTargets; ENSG00000142798; -.
DR   Orphanet; 1865; Dyssegmental dysplasia, Silverman-Handmaker type.
DR   Orphanet; 800; Schwartz-Jampel syndrome.
DR   PharmGKB; PA29537; -.
DR   eggNOG; KOG3509; Eukaryota.
DR   eggNOG; ENOG410XTD2; LUCA.
DR   GeneTree; ENSGT00860000133679; -.
DR   HOGENOM; HOG000049276; -.
DR   HOVERGEN; HBG008174; -.
DR   InParanoid; P98160; -.
DR   KO; K06255; -.
DR   OMA; TCRNLHH; -.
DR   OrthoDB; EOG091G048M; -.
DR   PhylomeDB; P98160; -.
DR   TreeFam; TF326548; -.
DR   Reactome; R-HSA-1474228; Degradation of the extracellular matrix.
DR   Reactome; R-HSA-1971475; A tetrasaccharide linker sequence is required for GAG synthesis.
DR   Reactome; R-HSA-2022928; HS-GAG biosynthesis.
DR   Reactome; R-HSA-2024096; HS-GAG degradation.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-3000157; Laminin interactions.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   Reactome; R-HSA-3560783; Defective B4GALT7 causes EDS, progeroid type.
DR   Reactome; R-HSA-3560801; Defective B3GAT3 causes JDSSDHD.
DR   Reactome; R-HSA-3656237; Defective EXT2 causes exostoses 2.
DR   Reactome; R-HSA-3656253; Defective EXT1 causes exostoses 1, TRPS2 and CHDS.
DR   Reactome; R-HSA-4420332; Defective B3GALT6 causes EDSP2 and SEMDJL1.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   SIGNOR; P98160; -.
DR   ChiTaRS; HSPG2; human.
DR   GeneWiki; Perlecan; -.
DR   GenomeRNAi; 3339; -.
DR   PRO; PR:P98160; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000142798; -.
DR   CleanEx; HS_HSPG2; -.
DR   ExpressionAtlas; P98160; baseline and differential.
DR   Genevisible; P98160; HS.
DR   GO; GO:0005604; C:basement membrane; TAS:CAFA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0006024; P:glycosaminoglycan biosynthetic process; TAS:Reactome.
DR   GO; GO:0006027; P:glycosaminoglycan catabolic process; TAS:Reactome.
DR   GO; GO:0030203; P:glycosaminoglycan metabolic process; TAS:Reactome.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 21.
DR   InterPro; IPR013320; ConA-like_dom.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013106; Ig_V-set.
DR   InterPro; IPR002049; Laminin_EGF.
DR   InterPro; IPR001791; Laminin_G.
DR   InterPro; IPR000034; Laminin_IV.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR000082; SEA_dom.
DR   Pfam; PF00008; EGF; 2.
DR   Pfam; PF07679; I-set; 9.
DR   Pfam; PF13895; Ig_2; 1.
DR   Pfam; PF00052; Laminin_B; 3.
DR   Pfam; PF00053; Laminin_EGF; 9.
DR   Pfam; PF00054; Laminin_G_1; 3.
DR   Pfam; PF00057; Ldl_recept_a; 4.
DR   PRINTS; PR00261; LDLRECEPTOR.
DR   SMART; SM00181; EGF; 11.
DR   SMART; SM00179; EGF_CA; 5.
DR   SMART; SM00180; EGF_Lam; 9.
DR   SMART; SM00409; IG; 22.
DR   SMART; SM00408; IGc2; 22.
DR   SMART; SM00406; IGv; 8.
DR   SMART; SM00281; LamB; 3.
DR   SMART; SM00282; LamG; 3.
DR   SMART; SM00192; LDLa; 4.
DR   SMART; SM00200; SEA; 1.
DR   SUPFAM; SSF48726; SSF48726; 22.
DR   SUPFAM; SSF49899; SSF49899; 3.
DR   SUPFAM; SSF57424; SSF57424; 4.
DR   PROSITE; PS00022; EGF_1; 9.
DR   PROSITE; PS01186; EGF_2; 6.
DR   PROSITE; PS50026; EGF_3; 4.
DR   PROSITE; PS01248; EGF_LAM_1; 11.
DR   PROSITE; PS50027; EGF_LAM_2; 8.
DR   PROSITE; PS50835; IG_LIKE; 22.
DR   PROSITE; PS50025; LAM_G_DOMAIN; 3.
DR   PROSITE; PS51115; LAMININ_IVA; 3.
DR   PROSITE; PS01209; LDLRA_1; 4.
DR   PROSITE; PS50068; LDLRA_2; 4.
DR   PROSITE; PS50024; SEA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Angiogenesis; Basement membrane; Calcium;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; EGF-like domain; Extracellular matrix; Glycoprotein;
KW   Heparan sulfate; Immunoglobulin domain; Laminin EGF-like domain;
KW   Metal-binding; Polymorphism; Proteoglycan; Reference proteome; Repeat;
KW   Secreted; Signal.
FT   SIGNAL        1     21       {ECO:0000255}.
FT   CHAIN        22   4391       Basement membrane-specific heparan
FT                                sulfate proteoglycan core protein.
FT                                /FTId=PRO_0000026696.
FT   CHAIN      3687   4391       Endorepellin.
FT                                /FTId=PRO_0000391621.
FT   CHAIN      4197   4391       LG3 peptide.
FT                                /FTId=PRO_0000391622.
FT   DOMAIN       80    191       SEA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00188}.
FT   DOMAIN      198    235       LDL-receptor class A 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      284    320       LDL-receptor class A 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      324    360       LDL-receptor class A 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      367    404       LDL-receptor class A 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      405    504       Ig-like C2-type 1.
FT   DOMAIN      521    530       Laminin EGF-like 1; first part.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00460}.
FT   DOMAIN      538    730       Laminin IV type A 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00458}.
FT   DOMAIN      731    763       Laminin EGF-like 1; second part.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00460}.
FT   DOMAIN      764    813       Laminin EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00460}.
FT   DOMAIN      814    871       Laminin EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00460}.
FT   DOMAIN      879    923       Laminin EGF-like 4; truncated.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00460}.
FT   DOMAIN      924    933       Laminin EGF-like 5; first part.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00460}.
FT   DOMAIN      941   1125       Laminin IV type A 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00458}.
FT   DOMAIN     1126   1158       Laminin EGF-like 5; second part.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00460}.
FT   DOMAIN     1159   1208       Laminin EGF-like 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00460}.
FT   DOMAIN     1209   1265       Laminin EGF-like 7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00460}.
FT   DOMAIN     1275   1324       Laminin EGF-like 8. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00460}.
FT   DOMAIN     1325   1334       Laminin EGF-like 9; first part.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00460}.
FT   DOMAIN     1344   1529       Laminin IV type A 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00458}.
FT   DOMAIN     1530   1562       Laminin EGF-like 9; second part.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00460}.
FT   DOMAIN     1563   1612       Laminin EGF-like 10.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00460}.
FT   DOMAIN     1613   1670       Laminin EGF-like 11.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00460}.
FT   DOMAIN     1677   1771       Ig-like C2-type 2.
FT   DOMAIN     1772   1865       Ig-like C2-type 3.
FT   DOMAIN     1866   1955       Ig-like C2-type 4.
FT   DOMAIN     1956   2051       Ig-like C2-type 5.
FT   DOMAIN     2052   2151       Ig-like C2-type 6.
FT   DOMAIN     2152   2244       Ig-like C2-type 7.
FT   DOMAIN     2245   2340       Ig-like C2-type 8.
FT   DOMAIN     2341   2436       Ig-like C2-type 9.
FT   DOMAIN     2437   2533       Ig-like C2-type 10.
FT   DOMAIN     2534   2629       Ig-like C2-type 11.
FT   DOMAIN     2630   2726       Ig-like C2-type 12.
FT   DOMAIN     2727   2826       Ig-like C2-type 13.
FT   DOMAIN     2827   2924       Ig-like C2-type 14.
FT   DOMAIN     2925   3021       Ig-like C2-type 15.
FT   DOMAIN     3022   3112       Ig-like C2-type 16.
FT   DOMAIN     3113   3211       Ig-like C2-type 17.
FT   DOMAIN     3212   3298       Ig-like C2-type 18.
FT   DOMAIN     3299   3399       Ig-like C2-type 19.
FT   DOMAIN     3400   3488       Ig-like C2-type 20.
FT   DOMAIN     3489   3574       Ig-like C2-type 21.
FT   DOMAIN     3575   3662       Ig-like C2-type 22.
FT   DOMAIN     3663   3843       Laminin G-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00122}.
FT   DOMAIN     3844   3881       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     3884   3922       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     3928   4103       Laminin G-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00122}.
FT   DOMAIN     4104   4141       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     4143   4176       EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     4201   4389       Laminin G-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00122}.
FT   REGION     4149   4151       Mediates motor neuron attachment.
FT                                {ECO:0000255}.
FT   REGION     4299   4301       Mediates motor neuron attachment.
FT                                {ECO:0000255}.
FT   METAL      4258   4258       Calcium.
FT   METAL      4275   4275       Calcium; via carbonyl oxygen.
FT   METAL      4325   4325       Calcium; via carbonyl oxygen.
FT   METAL      4327   4327       Calcium.
FT   SITE       4196   4197       Cleavage; by BMP1.
FT   CARBOHYD     42     42       O-linked (GalNAc...) threonine.
FT                                {ECO:0000269|PubMed:22171320}.
FT   CARBOHYD     65     65       O-linked (Xyl...) (heparan sulfate)
FT                                serine. {ECO:0000255}.
FT   CARBOHYD     71     71       O-linked (Xyl...) (heparan sulfate)
FT                                serine. {ECO:0000255}.
FT   CARBOHYD     76     76       O-linked (Xyl...) (heparan sulfate)
FT                                serine. {ECO:0000255}.
FT   CARBOHYD     89     89       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    554    554       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   1755   1755       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   2121   2121       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12754519}.
FT   CARBOHYD   2995   2995       O-linked (Xyl...) (chondroitin sulfate)
FT                                serine. {ECO:0000255}.
FT   CARBOHYD   3072   3072       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   3105   3105       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   3279   3279       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   3780   3780       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   3836   3836       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   3933   3933       O-linked (Xyl...) (chondroitin sulfate)
FT                                serine. {ECO:0000255}.
FT   CARBOHYD   4068   4068       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   4179   4179       O-linked (Xyl...) (chondroitin sulfate)
FT                                serine. {ECO:0000255}.
FT   DISULFID    199    212       {ECO:0000250}.
FT   DISULFID    206    225       {ECO:0000250}.
FT   DISULFID    219    234       {ECO:0000250}.
FT   DISULFID    285    297       {ECO:0000250}.
FT   DISULFID    292    310       {ECO:0000250}.
FT   DISULFID    304    319       {ECO:0000250}.
FT   DISULFID    325    337       {ECO:0000250}.
FT   DISULFID    332    350       {ECO:0000250}.
FT   DISULFID    344    359       {ECO:0000250}.
FT   DISULFID    368    381       {ECO:0000250}.
FT   DISULFID    375    394       {ECO:0000250}.
FT   DISULFID    388    403       {ECO:0000250}.
FT   DISULFID    764    773       {ECO:0000250}.
FT   DISULFID    766    780       {ECO:0000250}.
FT   DISULFID    783    792       {ECO:0000250}.
FT   DISULFID    795    811       {ECO:0000250}.
FT   DISULFID    814    829       {ECO:0000250}.
FT   DISULFID    816    839       {ECO:0000250}.
FT   DISULFID    842    851       {ECO:0000250}.
FT   DISULFID    854    869       {ECO:0000250}.
FT   DISULFID    879    892       {ECO:0000250}.
FT   DISULFID    894    903       {ECO:0000250}.
FT   DISULFID    906    921       {ECO:0000250}.
FT   DISULFID   1159   1168       {ECO:0000250}.
FT   DISULFID   1161   1175       {ECO:0000250}.
FT   DISULFID   1178   1187       {ECO:0000250}.
FT   DISULFID   1190   1206       {ECO:0000250}.
FT   DISULFID   1209   1224       {ECO:0000250}.
FT   DISULFID   1211   1234       {ECO:0000250}.
FT   DISULFID   1237   1246       {ECO:0000250}.
FT   DISULFID   1249   1263       {ECO:0000250}.
FT   DISULFID   1275   1287       {ECO:0000250}.
FT   DISULFID   1277   1293       {ECO:0000250}.
FT   DISULFID   1295   1304       {ECO:0000250}.
FT   DISULFID   1307   1322       {ECO:0000250}.
FT   DISULFID   1563   1572       {ECO:0000250}.
FT   DISULFID   1565   1579       {ECO:0000250}.
FT   DISULFID   1582   1591       {ECO:0000250}.
FT   DISULFID   1594   1610       {ECO:0000250}.
FT   DISULFID   1613   1628       {ECO:0000250}.
FT   DISULFID   1615   1638       {ECO:0000250}.
FT   DISULFID   1641   1650       {ECO:0000250}.
FT   DISULFID   1653   1668       {ECO:0000250}.
FT   DISULFID   3819   3845       {ECO:0000250}.
FT   DISULFID   3848   3859       {ECO:0000250}.
FT   DISULFID   3853   3869       {ECO:0000250}.
FT   DISULFID   3871   3880       {ECO:0000250}.
FT   DISULFID   3888   3899       {ECO:0000250}.
FT   DISULFID   3893   3910       {ECO:0000250}.
FT   DISULFID   3912   3921       {ECO:0000250}.
FT   DISULFID   4076   4102       {ECO:0000250}.
FT   DISULFID   4108   4119       {ECO:0000250}.
FT   DISULFID   4113   4129       {ECO:0000250}.
FT   DISULFID   4131   4140       {ECO:0000250}.
FT   DISULFID   4147   4159       {ECO:0000250}.
FT   DISULFID   4153   4164       {ECO:0000250}.
FT   DISULFID   4166   4175       {ECO:0000250}.
FT   DISULFID   4355   4389       {ECO:0000269|PubMed:21996443}.
FT   VARIANT      68     68       D -> E (in dbSNP:rs1869780).
FT                                /FTId=VAR_047979.
FT   VARIANT     303    303       L -> H (in dbSNP:rs17460381).
FT                                /FTId=VAR_057051.
FT   VARIANT     638    638       M -> V (in dbSNP:rs1874792).
FT                                {ECO:0000269|PubMed:11101850,
FT                                ECO:0000269|PubMed:1569102,
FT                                ECO:0000269|PubMed:1730768}.
FT                                /FTId=VAR_047980.
FT   VARIANT     765    765       N -> S (in dbSNP:rs989994).
FT                                {ECO:0000269|PubMed:11101850,
FT                                ECO:0000269|PubMed:1569102,
FT                                ECO:0000269|PubMed:1730768}.
FT                                /FTId=VAR_047981.
FT   VARIANT    1186   1186       R -> Q (in dbSNP:rs2229481).
FT                                /FTId=VAR_047982.
FT   VARIANT    1323   1323       L -> V (in dbSNP:rs10917058).
FT                                /FTId=VAR_057052.
FT   VARIANT    1503   1503       A -> V (in dbSNP:rs897471).
FT                                {ECO:0000269|PubMed:11101850,
FT                                ECO:0000269|PubMed:1569102,
FT                                ECO:0000269|PubMed:1730768}.
FT                                /FTId=VAR_047983.
FT   VARIANT    1532   1532       C -> Y (in SJS1; dbSNP:rs137853248).
FT                                {ECO:0000269|PubMed:11101850}.
FT                                /FTId=VAR_014122.
FT   VARIANT    1758   1758       R -> Q (in dbSNP:rs2229483).
FT                                /FTId=VAR_047984.
FT   VARIANT    1919   1919       R -> C (in dbSNP:rs2229474).
FT                                /FTId=VAR_047985.
FT   VARIANT    1967   1967       V -> I (in dbSNP:rs2229475).
FT                                /FTId=VAR_047986.
FT   VARIANT    2980   2980       L -> H (in dbSNP:rs2229489).
FT                                {ECO:0000269|PubMed:1730768}.
FT                                /FTId=VAR_047987.
FT   VARIANT    2981   2981       V -> I (in dbSNP:rs2229490).
FT                                /FTId=VAR_047988.
FT   VARIANT    2995   2995       S -> G (in dbSNP:rs2229491).
FT                                {ECO:0000269|PubMed:1730768}.
FT                                /FTId=VAR_047989.
FT   VARIANT    3168   3168       A -> T (in dbSNP:rs2228349).
FT                                {ECO:0000269|PubMed:1730768}.
FT                                /FTId=VAR_047990.
FT   VARIANT    3256   3256       H -> Y (in dbSNP:rs2291827).
FT                                /FTId=VAR_047991.
FT   VARIANT    3530   3530       R -> W (in dbSNP:rs2270699).
FT                                /FTId=VAR_047992.
FT   VARIANT    3632   3632       R -> Q (in dbSNP:rs2229493).
FT                                {ECO:0000269|PubMed:1730768}.
FT                                /FTId=VAR_047993.
FT   VARIANT    3640   3640       V -> I (in dbSNP:rs17459097).
FT                                /FTId=VAR_047994.
FT   VARIANT    4331   4331       S -> N (in dbSNP:rs3736360).
FT                                /FTId=VAR_047995.
FT   MUTAGEN    4197   4197       D->I: Abolishes BMP1-mediated cleavage of
FT                                endorepellin.
FT                                {ECO:0000269|PubMed:15591058}.
FT   MUTAGEN    4258   4258       D->A: Retains proper folding. Reduced
FT                                calcium ion binding.
FT                                {ECO:0000269|PubMed:15591058}.
FT   MUTAGEN    4327   4327       N->A: Retains proper folding. Reduced
FT                                calcium ion binding.
FT                                {ECO:0000269|PubMed:15591058}.
FT   CONFLICT      6      6       A -> P (in Ref. 2; CAA44373 and 1;
FT                                AAA52700). {ECO:0000305}.
FT   CONFLICT     58     58       D -> Y (in Ref. 1; AAA52700).
FT                                {ECO:0000305}.
FT   CONFLICT    435    437       TPI -> APFL (in Ref. 2; CAA44373).
FT                                {ECO:0000305}.
FT   CONFLICT    450    450       H -> Q (in Ref. 2; CAA44373).
FT                                {ECO:0000305}.
FT   CONFLICT    502    502       R -> RA (in Ref. 2; CAA44373).
FT                                {ECO:0000305}.
FT   CONFLICT    793    793       N -> K (in Ref. 2; CAA44373).
FT                                {ECO:0000305}.
FT   CONFLICT    890    891       EA -> RT (in Ref. 6; AAB21121).
FT                                {ECO:0000305}.
FT   CONFLICT    909    909       G -> R (in Ref. 2; CAA44373 and 6;
FT                                AAB21121). {ECO:0000305}.
FT   CONFLICT   1102   1102       V -> L (in Ref. 6; AAB21121).
FT                                {ECO:0000305}.
FT   CONFLICT   1133   1133       R -> L (in Ref. 6; AAB21121).
FT                                {ECO:0000305}.
FT   CONFLICT   1222   1222       H -> L (in Ref. 6; AAB21121).
FT                                {ECO:0000305}.
FT   CONFLICT   1406   1406       D -> G (in Ref. 7; AAA52699).
FT                                {ECO:0000305}.
FT   CONFLICT   1410   1410       A -> G (in Ref. 7; AAA52699).
FT                                {ECO:0000305}.
FT   CONFLICT   1466   1470       EFWRR -> LNLRQ (in Ref. 7; AAA52699).
FT                                {ECO:0000305}.
FT   CONFLICT   1703   1704       SP -> RG (in Ref. 2; CAA44373).
FT                                {ECO:0000305}.
FT   CONFLICT   1753   1753       Q -> R (in Ref. 2; CAA44373).
FT                                {ECO:0000305}.
FT   CONFLICT   2038   2038       I -> M (in Ref. 1; AAA52700).
FT                                {ECO:0000305}.
FT   CONFLICT   2050   2050       P -> Q (in Ref. 2; CAA44373).
FT                                {ECO:0000305}.
FT   CONFLICT   2052   2052       P -> G (in Ref. 1; AAA52700).
FT                                {ECO:0000305}.
FT   CONFLICT   2093   2093       P -> H (in Ref. 2; CAA44373).
FT                                {ECO:0000305}.
FT   CONFLICT   2627   2627       S -> R (in Ref. 2; CAA44373).
FT                                {ECO:0000305}.
FT   CONFLICT   2770   2770       H -> Y (in Ref. 2; CAA44373).
FT                                {ECO:0000305}.
FT   CONFLICT   3241   3241       P -> R (in Ref. 2; CAA44373).
FT                                {ECO:0000305}.
FT   CONFLICT   3427   3427       R -> Q (in Ref. 1; AAA52700).
FT                                {ECO:0000305}.
FT   CONFLICT   4004   4004       S -> T (in Ref. 2; CAA44373).
FT                                {ECO:0000305}.
FT   CONFLICT   4135   4135       F -> I (in Ref. 2; CAA44373).
FT                                {ECO:0000305}.
FT   CONFLICT   4332   4332       V -> I (in Ref. 2; CAA44373).
FT                                {ECO:0000305}.
FT   TURN       4199   4202       {ECO:0000244|PDB:3SH4}.
FT   STRAND     4203   4214       {ECO:0000244|PDB:3SH4}.
FT   HELIX      4216   4219       {ECO:0000244|PDB:3SH4}.
FT   STRAND     4228   4236       {ECO:0000244|PDB:3SH4}.
FT   STRAND     4239   4246       {ECO:0000244|PDB:3SH4}.
FT   STRAND     4259   4265       {ECO:0000244|PDB:3SH4}.
FT   STRAND     4268   4274       {ECO:0000244|PDB:3SH4}.
FT   STRAND     4279   4283       {ECO:0000244|PDB:3SH4}.
FT   STRAND     4290   4292       {ECO:0000244|PDB:3SH4}.
FT   STRAND     4294   4301       {ECO:0000244|PDB:3SH4}.
FT   STRAND     4304   4309       {ECO:0000244|PDB:3SH4}.
FT   STRAND     4315   4318       {ECO:0000244|PDB:3SH4}.
FT   STRAND     4320   4322       {ECO:0000244|PDB:3SH5}.
FT   STRAND     4332   4335       {ECO:0000244|PDB:3SH4}.
FT   HELIX      4340   4343       {ECO:0000244|PDB:3SH4}.
FT   TURN       4344   4346       {ECO:0000244|PDB:3SH4}.
FT   STRAND     4353   4363       {ECO:0000244|PDB:3SH4}.
FT   STRAND     4366   4368       {ECO:0000244|PDB:3SH5}.
FT   TURN       4376   4378       {ECO:0000244|PDB:3SH4}.
FT   STRAND     4381   4388       {ECO:0000244|PDB:3SH4}.
SQ   SEQUENCE   4391 AA;  468830 MW;  C587660E24C83324 CRC64;
     MGWRAAGALL LALLLHGRLL AVTHGLRAYD GLSLPEDIET VTASQMRWTH SYLSDDEDML
     ADSISGDDLG SGDLGSGDFQ MVYFRALVNF TRSIEYSPQL EDAGSREFRE VSEAVVDTLE
     SEYLKIPGDQ VVSVVFIKEL DGWVFVELDV GSEGNADGAQ IQEMLLRVIS SGSVASYVTS
     PQGFQFRRLG TVPQFPRACT EAEFACHSYN ECVALEYRCD RRPDCRDMSD ELNCEEPVLG
     ISPTFSLLVE TTSLPPRPET TIMRQPPVTH APQPLLPGSV RPLPCGPQEA ACRNGHCIPR
     DYLCDGQEDC EDGSDELDCG PPPPCEPNEF PCGNGHCALK LWRCDGDFDC EDRTDEANCP
     TKRPEEVCGP TQFRCVSTNM CIPASFHCDE ESDCPDRSDE FGCMPPQVVT PPRESIQASR
     GQTVTFTCVA IGVPTPIINW RLNWGHIPSH PRVTVTSEGG RGTLIIRDVK ESDQGAYTCE
     AMNARGMVFG IPDGVLELVP QRGPCPDGHF YLEHSAACLP CFCFGITSVC QSTRRFRDQI
     RLRFDQPDDF KGVNVTMPAQ PGTPPLSSTQ LQIDPSLHEF QLVDLSRRFL VHDSFWALPE
     QFLGNKVDSY GGSLRYNVRY ELARGMLEPV QRPDVVLMGA GYRLLSRGHT PTQPGALNQR
     QVQFSEEHWV HESGRPVQRA ELLQVLQSLE AVLIQTVYNT KMASVGLSDI AMDTTVTHAT
     SHGRAHSVEE CRCPIGYSGL SCESCDAHFT RVPGGPYLGT CSGCNCNGHA SSCDPVYGHC
     LNCQHNTEGP QCNKCKAGFF GDAMKATATS CRPCPCPYID ASRRFSDTCF LDTDGQATCD
     ACAPGYTGRR CESCAPGYEG NPIQPGGKCR PVNQEIVRCD ERGSMGTSGE ACRCKNNVVG
     RLCNECADGS FHLSTRNPDG CLKCFCMGVS RHCTSSSWSR AQLHGASEEP GHFSLTNAAS
     THTTNEGIFS PTPGELGFSS FHRLLSGPYF WSLPSRFLGD KVTSYGGELR FTVTQRSQPG
     STPLHGQPLV VLQGNNIILE HHVAQEPSPG QPSTFIVPFR EQAWQRPDGQ PATREHLLMA
     LAGIDTLLIR ASYAQQPAES RVSGISMDVA VPEETGQDPA LEVEQCSCPP GYRGPSCQDC
     DTGYTRTPSG LYLGTCERCS CHGHSEACEP ETGACQGCQH HTEGPRCEQC QPGYYGDAQR
     GTPQDCQLCP CYGDPAAGQA AHTCFLDTDG HPTCDACSPG HSGRHCERCA PGYYGNPSQG
     QPCQRDSQVP GPIGCNCDPQ GSVSSQCDAA GQCQCKAQVE GLTCSHCRPH HFHLSASNPD
     GCLPCFCMGI TQQCASSAYT RHLISTHFAP GDFQGFALVN PQRNSRLTGE FTVEPVPEGA
     QLSFGNFAQL GHESFYWQLP ETYQGDKVAA YGGKLRYTLS YTAGPQGSPL SDPDVQITGN
     NIMLVASQPA LQGPERRSYE IMFREEFWRR PDGQPATREH LLMALADLDE LLIRATFSSV
     PLAASISAVS LEVAQPGPSN RPRALEVEEC RCPPGYIGLS CQDCAPGYTR TGSGLYLGHC
     ELCECNGHSD LCHPETGACS QCQHNAAGEF CELCAPGYYG DATAGTPEDC QPCACPLTNP
     ENMFSRTCES LGAGGYRCTA CEPGYTGQYC EQCGPGYVGN PSVQGGQCLP ETNQAPLVVE
     VHPARSIVPQ GGSHSLRCQV SGSPPHYFYW SREDGRPVPS GTQQRHQGSE LHFPSVQPSD
     AGVYICTCRN LHQSNTSRAE LLVTEAPSKP ITVTVEEQRS QSVRPGADVT FICTAKSKSP
     AYTLVWTRLH NGKLPTRAMD FNGILTIRNV QLSDAGTYVC TGSNMFAMDQ GTATLHVQAS
     GTLSAPVVSI HPPQLTVQPG QLAEFRCSAT GSPTPTLEWT GGPGGQLPAK AQIHGGILRL
     PAVEPTDQAQ YLCRAHSSAG QQVARAVLHV HGGGGPRVQV SPERTQVHAG RTVRLYCRAA
     GVPSATITWR KEGGSLPPQA RSERTDIATL LIPAITTADA GFYLCVATSP AGTAQARIQV
     VVLSASDASP PPVKIESSSP SVTEGQTLDL NCVVAGSAHA QVTWYRRGGS LPPHTQVHGS
     RLRLPQVSPA DSGEYVCRVE NGSGPKEASI TVSVLHGTHS GPSYTPVPGS TRPIRIEPSS
     SHVAEGQTLD LNCVVPGQAH AQVTWHKRGG SLPARHQTHG SLLRLHQVTP ADSGEYVCHV
     VGTSGPLEAS VLVTIEASVI PGPIPPVRIE SSSSTVAEGQ TLDLSCVVAG QAHAQVTWYK
     RGGSLPARHQ VRGSRLYIFQ ASPADAGQYV CRASNGMEAS ITVTVTGTQG ANLAYPAGST
     QPIRIEPSSS QVAEGQTLDL NCVVPGQSHA QVTWHKRGGS LPVRHQTHGS LLRLYQASPA
     DSGEYVCRVL GSSVPLEASV LVTIEPAGSV PALGVTPTVR IESSSSQVAE GQTLDLNCLV
     AGQAHAQVTW HKRGGSLPAR HQVHGSRLRL LQVTPADSGE YVCRVVGSSG TQEASVLVTI
     QQRLSGSHSQ GVAYPVRIES SSASLANGHT LDLNCLVASQ APHTITWYKR GGSLPSRHQI
     VGSRLRIPQV TPADSGEYVC HVSNGAGSRE TSLIVTIQGS GSSHVPSVSP PIRIESSSPT
     VVEGQTLDLN CVVARQPQAI ITWYKRGGSL PSRHQTHGSH LRLHQMSVAD SGEYVCRANN
     NIDALEASIV ISVSPSAGSP SAPGSSMPIR IESSSSHVAE GETLDLNCVV PGQAHAQVTW
     HKRGGSLPSH HQTRGSRLRL HHVSPADSGE YVCRVMGSSG PLEASVLVTI EASGSSAVHV
     PAPGGAPPIR IEPSSSRVAE GQTLDLKCVV PGQAHAQVTW HKRGGNLPAR HQVHGPLLRL
     NQVSPADSGE YSCQVTGSSG TLEASVLVTI EPSSPGPIPA PGLAQPIYIE ASSSHVTEGQ
     TLDLNCVVPG QAHAQVTWYK RGGSLPARHQ THGSQLRLHL VSPADSGEYV CRAASGPGPE
     QEASFTVTVP PSEGSSYRLR SPVISIDPPS STVQQGQDAS FKCLIHDGAA PISLEWKTRN
     QELEDNVHIS PNGSIITIVG TRPSNHGTYR CVASNAYGVA QSVVNLSVHG PPTVSVLPEG
     PVWVKVGKAV TLECVSAGEP RSSARWTRIS STPAKLEQRT YGLMDSHAVL QISSAKPSDA
     GTYVCLAQNA LGTAQKQVEV IVDTGAMAPG APQVQAEEAE LTVEAGHTAT LRCSATGSPA
     PTIHWSKLRS PLPWQHRLEG DTLIIPRVAQ QDSGQYICNA TSPAGHAEAT IILHVESPPY
     ATTVPEHASV QAGETVQLQC LAHGTPPLTF QWSRVGSSLP GRATARNELL HFERAAPEDS
     GRYRCRVTNK VGSAEAFAQL LVQGPPGSLP ATSIPAGSTP TVQVTPQLET KSIGASVEFH
     CAVPSDRGTQ LRWFKEGGQL PPGHSVQDGV LRIQNLDQSC QGTYICQAHG PWGKAQASAQ
     LVIQALPSVL INIRTSVQTV VVGHAVEFEC LALGDPKPQV TWSKVGGHLR PGIVQSGGVV
     RIAHVELADA GQYRCTATNA AGTTQSHVLL LVQALPQISM PQEVRVPAGS AAVFPCIASG
     YPTPDISWSK LDGSLPPDSR LENNMLMLPS VRPQDAGTYV CTATNRQGKV KAFAHLQVPE
     RVVPYFTQTP YSFLPLPTIK DAYRKFEIKI TFRPDSADGM LLYNGQKRVP GSPTNLANRQ
     PDFISFGLVG GRPEFRFDAG SGMATIRHPT PLALGHFHTV TLLRSLTQGS LIVGDLAPVN
     GTSQGKFQGL DLNEELYLGG YPDYGAIPKA GLSSGFIGCV RELRIQGEEI VFHDLNLTAH
     GISHCPTCRD RPCQNGGQCH DSESSSYVCV CPAGFTGSRC EHSQALHCHP EACGPDATCV
     NRPDGRGYTC RCHLGRSGLR CEEGVTVTTP SLSGAGSYLA LPALTNTHHE LRLDVEFKPL
     APDGVLLFSG GKSGPVEDFV SLAMVGGHLE FRYELGSGLA VLRSAEPLAL GRWHRVSAER
     LNKDGSLRVN GGRPVLRSSP GKSQGLNLHT LLYLGGVEPS VPLSPATNMS AHFRGCVGEV
     SVNGKRLDLT YSFLGSQGIG QCYDSSPCER QPCQHGATCM PAGEYEFQCL CRDGFKGDLC
     EHEENPCQLR EPCLHGGTCQ GTRCLCLPGF SGPRCQQGSG HGIAESDWHL EGSGGNDAPG
     QYGAYFHDDG FLAFPGHVFS RSLPEVPETI ELEVRTSTAS GLLLWQGVEV GEAGQGKDFI
     SLGLQDGHLV FRYQLGSGEA RLVSEDPIND GEWHRVTALR EGRRGSIQVD GEELVSGRSP
     GPNVAVNAKG SVYIGGAPDV ATLTGGRFSS GITGCVKNLV LHSARPGAPP PQPLDLQHRA
     QAGANTRPCP S
//
